ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1382627
CHEMBL1382627
Compound Name SULFADIAZINE, SILVER
ChEMBL Synonyms SSD AF | SULFADIAZINE SILVER | FLAMAZINE | SULFADIAZINE, SILVER | THERMAZENE | SILVER SULFADIAZINE | FLAMMACERIUM | SILDAFLO | SILVADENE
Max Phase 4 (Approved)
Trade Names FLAMAZINE | FLAMMACERIUM | SILDAFLO | SILVADENE | SSD AF | THERMAZENE
Molecular Formula C10H9AgN4O2S

Additional synonyms for CHEMBL1382627 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES [Ag+].Nc1ccc(cc1)S(=O)(=O)[N-]c2ncccn2
Standard InChI InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6 ...
Download InChI
Standard InChI Key UEJSSZHHYBHCEL-UHFFFAOYSA-N

Sources

  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1382627

Molecule Features

CHEMBL1382627 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:N Parenteral:N Topical:Y Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Bacterial dihydropteroate synthase inhibitor Bacterial dihydropteroate synthase DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
OsteomyelitisD010019EFO:0003102osteomyelitis0ClinicalTrials
ClinicalTrials
InfectionD007239EFO:0000544infection1ClinicalTrials

Clinical Data

ClinicalTrials.gov SULFADIAZINE, SILVER
The Cochrane Collaboration SULFADIAZINE, SILVER

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1382627. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL3594 Carbonic anhydrase IX Homo sapiens 0.998
CHEMBL205 Carbonic anhydrase II Homo sapiens 0.997
CHEMBL281 Carbonic anhydrase IV Bos taurus 0.992
CHEMBL261 Carbonic anhydrase I Homo sapiens 0.992
CHEMBL4296 Sodium channel protein type IX alpha subunit Homo sapiens 0.974
CHEMBL3242 Carbonic anhydrase XII Homo sapiens 0.925
CHEMBL3371 Serotonin 6 (5-HT6) receptor Homo sapiens 0.904
CHEMBL3025 Carbonic anhydrase VI Homo sapiens 0.896
CHEMBL301 Cyclin-dependent kinase 2 Homo sapiens 0.896
CHEMBL5815 C-C chemokine receptor type 9 Homo sapiens 0.804
CHEMBL3510 Carbonic anhydrase XIV Homo sapiens 0.594
CHEMBL4789 Carbonic anhydrase VA Homo sapiens 0.411
CHEMBL308 Cyclin-dependent kinase 1 Homo sapiens 0.351



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL3594 Carbonic anhydrase IX Homo sapiens 0.996
CHEMBL205 Carbonic anhydrase II Homo sapiens 0.995
CHEMBL281 Carbonic anhydrase IV Bos taurus 0.988
CHEMBL261 Carbonic anhydrase I Homo sapiens 0.986
CHEMBL4296 Sodium channel protein type IX alpha subunit Homo sapiens 0.948
CHEMBL3242 Carbonic anhydrase XII Homo sapiens 0.888
CHEMBL3371 Serotonin 6 (5-HT6) receptor Homo sapiens 0.881
CHEMBL5815 C-C chemokine receptor type 9 Homo sapiens 0.847
CHEMBL1980 Sodium channel protein type V alpha subunit Homo sapiens 0.705
CHEMBL308 Cyclin-dependent kinase 1 Homo sapiens 0.627
CHEMBL301 Cyclin-dependent kinase 2 Homo sapiens 0.606
CHEMBL210 Beta-2 adrenergic receptor Homo sapiens 0.554
CHEMBL3510 Carbonic anhydrase XIV Homo sapiens 0.508
CHEMBL3025 Carbonic anhydrase VI Homo sapiens 0.420

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
250.3 250.0524 0.86 3 97.97 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 2 0 6 3 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
6.81 1.57 -.07 -.8 2 17 0.79

Structural Alerts

There are 4 structural alerts for CHEMBL1382627. To view alerts please click here.

Compound Cross References

ATC D - DERMATOLOGICALS
D06 - ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D06B - CHEMOTHERAPEUTICS FOR TOPICAL USE
D06BA - Sulfonamides
D06BA51 - silver sulfadiazine, combinations

D - DERMATOLOGICALS
D06 - ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D06B - CHEMOTHERAPEUTICS FOR TOPICAL USE
D06BA - Sulfonamides
D06BA01 - silver sulfadiazine

ChemSpider ChemSpider:UEJSSZHHYBHCEL-UHFFFAOYSA-N
DailyMed silver sulfadiazine
PubChem SID: 124894330 SID: 144206550 SID: 144207020 SID: 8139967

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1382627



ACToR 22199-08-2
Brenda 118231
ChEBI 9142
ChemicalBook CB4744940
DrugBank DB05245
eMolecules 36754610 902466 513821
EPA CompTox Dashboard DTXSID4048646
FDA SRS W46JY43EJR
MolPort MolPort-003-934-423 MolPort-003-986-619
PharmGKB PA164744951
PubChem 5459124 452254 441244
PubChem: Thomson Pharma 16639812
SureChEMBL SCHEMBL15633 SCHEMBL16043898

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/UEJSSZHHYBHCEL-UHFFFAOYSA-N spacer
spacer